This HTML5 document contains 50 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n11http://localhost/temp/predkladatel/
n6http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n13http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n16http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11120%2F14%3A43908242%21RIV15-MSM-11120___/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
n12http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n8http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11120%2F14%3A43908242%21RIV15-MSM-11120___
rdf:type
n13:Vysledek skos:Concept
dcterms:description
Bioresorbable vascular scaffolds (BVSs) have been studied in chronic coronary artery disease, but not in acute ST-segment elevation myocardial infarction (STEMI). This prospective multicentre study analysed the feasibility and safety of BVS implantation during primary percutaneous coronary intervention (p-PCI) in STEMI. Bioresorbable vascular scaffold implantation became the default strategy for all consecutive STEMI patients between 15 December 2012 and 30 August 2013. A total of 142 patients underwent p-PCI; 41 of them (28.9%) fulfilled the inclusion/exclusion criteria for BVS implantation. The BVS device success was 98%, thrombolysis in myocardial infarction 3 flow was restored in 95% of patients, and acute scaffold recoil was 9.7%. An optical coherence tomography (OCT) substudy (21 patients) demonstrated excellent procedural results with only a 1.1% rate of scaffold strut malapposition. Edge dissections were present in a 38% of patients, but were small and clinically silent. Reference vessel diameter measured by quantitative coronary angiography was significantly lower than that measured by OCT by 0.29 (±0.56) mm, P = 0.028. Clinical outcomes were compared between BVS group and Control group; the latter was formed by patients who had implanted metallic stent and were in Killip Class I or II. Combined clinical endpoint was defined as death, myocardial infarction, or target vessel revascularization. Event-free survival was the same in both groups; 95% for BVS and 93% for Control group, P = 0.674. Conclusion Bioresorbable vascular scaffold implantation in acute STEMI is feasible and safe. The procedural results evaluated by angiography and OCT are excellent. The early clinical results are encouraging. Bioresorbable vascular scaffolds (BVSs) have been studied in chronic coronary artery disease, but not in acute ST-segment elevation myocardial infarction (STEMI). This prospective multicentre study analysed the feasibility and safety of BVS implantation during primary percutaneous coronary intervention (p-PCI) in STEMI. Bioresorbable vascular scaffold implantation became the default strategy for all consecutive STEMI patients between 15 December 2012 and 30 August 2013. A total of 142 patients underwent p-PCI; 41 of them (28.9%) fulfilled the inclusion/exclusion criteria for BVS implantation. The BVS device success was 98%, thrombolysis in myocardial infarction 3 flow was restored in 95% of patients, and acute scaffold recoil was 9.7%. An optical coherence tomography (OCT) substudy (21 patients) demonstrated excellent procedural results with only a 1.1% rate of scaffold strut malapposition. Edge dissections were present in a 38% of patients, but were small and clinically silent. Reference vessel diameter measured by quantitative coronary angiography was significantly lower than that measured by OCT by 0.29 (±0.56) mm, P = 0.028. Clinical outcomes were compared between BVS group and Control group; the latter was formed by patients who had implanted metallic stent and were in Killip Class I or II. Combined clinical endpoint was defined as death, myocardial infarction, or target vessel revascularization. Event-free survival was the same in both groups; 95% for BVS and 93% for Control group, P = 0.674. Conclusion Bioresorbable vascular scaffold implantation in acute STEMI is feasible and safe. The procedural results evaluated by angiography and OCT are excellent. The early clinical results are encouraging.
dcterms:title
Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study Prague 19 Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study Prague 19
skos:prefLabel
Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study Prague 19 Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study Prague 19
skos:notation
RIV/00216208:11120/14:43908242!RIV15-MSM-11120___
n4:aktivita
n14:I
n4:aktivity
I
n4:cisloPeriodika
12
n4:dodaniDat
n8:2015
n4:domaciTvurceVysledku
n6:8917175 n6:2228734 n6:8731977 n6:7530242 n6:6147755 n6:1304585
n4:druhVysledku
n15:J
n4:duvernostUdaju
n9:S
n4:entitaPredkladatele
n16:predkladatel
n4:idSjednocenehoVysledku
5481
n4:idVysledku
RIV/00216208:11120/14:43908242
n4:jazykVysledku
n18:eng
n4:klicovaSlova
Optical coherence tomography; Primary PCI; Acute myocardial infarction; Biodegradable stent; Bioresorbable vascular scaffold
n4:klicoveSlovo
n10:Optical%20coherence%20tomography n10:Biodegradable%20stent n10:Primary%20PCI n10:Bioresorbable%20vascular%20scaffold n10:Acute%20myocardial%20infarction
n4:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n4:kontrolniKodProRIV
[3F053928A74D]
n4:nazevZdroje
European Heart Journal
n4:obor
n17:FA
n4:pocetDomacichTvurcuVysledku
6
n4:pocetTvurcuVysledku
8
n4:rokUplatneniVysledku
n8:2014
n4:svazekPeriodika
35
n4:tvurceVysledku
Widimský, Petr Buděšínský, Tomáš Prodanov, Petko Lisa, Libor Toušek, Petr Kočka, Viktor
n4:wos
000334120600010
s:issn
0195-668X
s:numberOfPages
8
n12:doi
10.1093/eurheartj/eht545
n11:organizacniJednotka
11120